Status:
COMPLETED
A Study to Learn More About the Menopausal Hormone Therapies in Korea
Lead Sponsor:
Pfizer
Conditions:
Menopause
Bone Demineralization
Eligibility:
FEMALE
40-59 years
Brief Summary
The purpose of this study is to learn about how the commonly used menopausal hormone therapies were prescribed and taken in practice. This is done by using healthcare database, to study the overall da...
Eligibility Criteria
Inclusion
- Patients aged 40-59 years at cohort entry date
- Patients who had at least one inpatient or outpatient diagnosis of menopausal symptoms between 01 Jan 2012 and 31 Dec 2019 with any of following diagnosis codes: N95.1, N95.2, N95.3, N95.8, N95.9, M80.0, M81.0, M81.99, M85.99
Exclusion
- Patients diagnosed with breast cancer (C50, D05), endometrial cancer (C54.1), and granulosa cell tumor (C56) within 1 year prior to the index date.
- Patients diagnosed with coronary heart disease (I20-I25, I51.6), stroke (I60-64), and VTE (I80.2, I80.3 I26) within 1 year prior to the index date.
- Patients diagnosed with viral hepatitis (B16-B19), cirrhosis (K70.2-K70.4, K71.7, K72.0-K72.1, K72.9, K74.0-K74.6, K76.1, K76.6-K76.7, R18, I85.0, I85.9, I86.4, I86.8, I98.2-I98.3), and hepatic cancer (C22) within 1 year prior to the index date.
- Patients diagnosed with gallbladder disease (K80, K81, K82, K83, K85.1), gallbladder cancer (C23), extrahepatic bile duct cancer (C24) within 1 year prior to the index date.
Key Trial Info
Start Date :
September 12 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 11 2024
Estimated Enrollment :
1036294 Patients enrolled
Trial Details
Trial ID
NCT06033521
Start Date
September 12 2023
End Date
March 11 2024
Last Update
April 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer South Korea
Seoul, South Korea